metronidazole has been researched along with Necrotizing Pyelonephritis in 6 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ceftolozane/tazobactam is an antibacterial with potent activity against Gram-negative pathogens and is approved for the treatment of cIAI (with metronidazole) and cUTI (including pyelonephritis)." | 5.24 | Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam. ( Huntington, JA; Long, J; Popejoy, MW, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Popejoy, MW | 1 |
| Long, J | 1 |
| Huntington, JA | 1 |
| Gupta, P | 1 |
| Gupta, R | 2 |
| Jandial, K | 1 |
| Samotra, S | 1 |
| Rana, V | 1 |
| Gupta, S | 1 |
| Singh, J | 1 |
| Christodoulidou, M | 1 |
| Thomas, M | 1 |
| Sharma, SD | 1 |
| DRAPER, JW | 1 |
| AKBARI, A | 1 |
| WARD, JN | 1 |
| Pühse, G | 1 |
| Roos, N | 1 |
| Ludwig, K | 1 |
| Hertle, L | 1 |
| Ingham, HR | 1 |
| Rich, GE | 1 |
| Selkon, JB | 1 |
| Hale, JH | 1 |
| Roxby, CM | 1 |
| Betty, MJ | 1 |
| Johnson, RW | 1 |
| Uldall, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections[NCT01445678] | Phase 3 | 494 participants (Actual) | Interventional | 2011-12-23 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis[NCT01345929] | Phase 3 | 558 participants (Actual) | Interventional | 2011-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 83.0 |
| Meropenem as Treatment for cIAI | 87.3 |
Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 89.2 |
| Meropenem as Treatment for cIAI | 92.3 |
Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 97.1 |
| Meropenem as Treatment for cIAI | 97.5 |
Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 100 |
| Meropenem as Treatment for cIAI | 99.3 |
Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit. (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 82.5 |
| Meropenem as Treatment for cIAI | 86.6 |
Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 94.2 |
| Meropenem as Treatment for cIAI | 94.7 |
(NCT01345929)
Timeframe: Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 as Treatment for cUTI | 76.9 |
| Levofloxacin as Treatment for cUTI | 68.4 |
(NCT01345929)
Timeframe: Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 as Treatment for cUTI | 83.3 |
| Levofloxacin as Treatment for cUTI | 75.4 |
1 trial available for metronidazole and Necrotizing Pyelonephritis
| Article | Year |
|---|---|
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
5 other studies available for metronidazole and Necrotizing Pyelonephritis
| Article | Year |
|---|---|
Emphysematous pyelonephritis in the setting of diabetes mellitus.
Topics: Anti-Infective Agents; Diabetes Mellitus, Type 2; Diagnosis, Differential; Emphysema; Escherichia co | 2011 |
Hydronephrosis and loin pain as a presentation of tubo-ovarian abscess developing after Mirena coil removal.
Topics: Abdominal Pain; Abscess; Adult; Anti-Infective Agents; Appendicitis; Device Removal; Diagnosis, Diff | 2012 |
THERAPEUTIC PROBLEMS IN URINARY INFECTIONS.
Topics: Chloramphenicol; Enterobacter aerogenes; Escherichia coli Infections; Humans; Hydrocortisone; Imidaz | 1964 |
[Intra- and peri-renal gas formation. Bilateral emphysematous pyelonephritis].
Topics: Aged; Combined Modality Therapy; Fatal Outcome; Female; Humans; Imipenem; Kidney; Lumbar Vertebrae; | 1999 |
Treatment with metronidazole of three patients with serious infections due to Bacteroides fragilis.
Topics: Adolescent; Bacteroides fragilis; Bacteroides Infections; Brain Abscess; Female; Humans; Kidney Fail | 1975 |